Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfer
- Development stage
- Unknown
- Lead developer
- Alde Medi Impex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alfer is an oral hematinic combination supplement developed and marketed by Alde Medi Impex. It is formulated to manage and prevent iron deficiency anemia, support red blood cell production, and maintain overall energy levels. The supplement typically contains a combination of highly bioavailable iron (such as ferrous bisglycinate or sodium feredetate), zinc bisglycinate, folic acid (vitamin B9), and cyanocobalamin (vitamin B12). These active ingredients work synergistically to promote hemoglobin synthesis, support DNA synthesis and cell division, and maintain healthy nerve function.
- Brand names
- Alfer
Beyond the preview
Go deeper on Alfer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alfer.